[Therapy of subacute sclerosing panencephalitis with intrathecal alpha-interferon]

Clinical benefits were noted in subacute sclerosing panencephalitis patients treated with a total of 15 x 10(6) I.U. of alpha-interferon administered intrathecally over a period of one month. Improvements did not correlate with major variations in anti-measles IgG titers or variation of pattern, IgG subclass or light chain composition of CSF oligoclonal bands.